Company profile
EdiTy Therapeutics company profile
EdiTy Therapeutics is a biotechnology company that develops a gene-editing technology designed for in-vivo gene-editing of target cells. It utilizes T-cells machinery to directly deliver gene-editing agents to target cells in-vivo. Michal Golan Mashiach established the Rehovot, HaMerkaz, Israel-based company in 2020.
Business identity
- Website
- http://www.edity-tx.com
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Revenue range
- $0-$1M
- Founded
- 2020-01-01, Year
Headquarters
- Headquarters
- Reẖovot, Central District, Israel
- Country code
- IL
- Continent
- Asia